A Phase 2 Open-Label Study to Evaluate the Efficacy and Safety of Ustekinumab, a Human Monoclonal Anti-IL-12/IL-23 Antibody, in Patients With Behcet Disease
Phase of Trial: Phase II
Latest Information Update: 15 Nov 2017
At a glance
- Drugs Ustekinumab (Primary)
- Indications Behcet's syndrome
- Focus Therapeutic Use
- Acronyms STELABEC
- 08 Nov 2017 Planned End Date changed from 1 Jan 2019 to 1 Apr 2020.
- 08 Nov 2017 Planned primary completion date changed from 1 Jul 2018 to 1 Apr 2019.
- 08 Nov 2017 Status changed from not yet recruiting to recruiting.